Inavolisib

TNBC

Hu HaiSmall moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

10 Active assets in the TNBC cohort.

Asset / Sponsor	Phase	Rating
pm8002 Biotheus Inc.	Phase 3	B
Utidelone Fudan University	Phase 3	B
human vascular endothelial growth factor receptor 1 (VEGFR-1) fragment 129-228 comprising the second extracellular domain of the VEGF receptor (VEGFR-D2), [N<sup>196</sup>>A<sup>68</sup>]-variant, anti-(human vascular endothelial growth factor (VEGF) (1-100 in the current sequence) fused, via a (G4S)3 peptide linker (101-115), to gamma 1 heavy chain (116-563) [VH (Homo sapiens IGHV3-2304 -(IGHD) -IGHJ401, CDR-Kabat [5.17.9] (146-150.165-181.214-222)) (116-233) -Homo sapiens IGHG103 (CH1 (234-331), hinge (332-346), CH2 S<sup>414</sup>>A, E<sup>449</sup>>A, K<sup>450</sup>>A (347-456), CH3 (457-561), CHS (562-563)) (234-563)], (336-214')-disulfide with kappa light chain (1'-214') [V-KAPPA (Homo sapiens IGKV1-1201 -IGKJ101, CDRKabat [11.7.9] (24'-34'.50'-56'.89'-97')) (1'-107') -Homo sapiens IGKC01 (108'-214')]; dimer (342-342'', 345-345'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	Phase 2	CCC
hb0025 Huabo Biopharm Co., Ltd.	Phase 2	CCC
Shr-A1921 Fudan University	Phase 2	CCC